|
[1]
|
China antimicrobial surveillance network. 2023. http://www.chinets.com.[2023-10-27]. (In Chinese).http://www.chinets.com |
|
[2]
|
Clinical and Laboratory Standards Institute. M100 Performance standards for antimicrobial susceptibility testing. 32nd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2022. https://www.standards-global.com/wp-content/uploads/pdfs/preview/2247002. [2023-10-27].https://www.standards-global.com/wp-content/uploads/pdfs/preview/2247002 |
|
[3]
|
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.1, 2023. https://www.eucast.org/clinical_breakpoints. [2023-10-27].https://www.eucast.org/clinical_breakpoints |
|
[4]
|
U.S. Food & Drug Administration. Tigecycline-injection products. 2023. https://www.fda.gov/drugs/development-resources/tigecycline-injection-products. [2023-1-26].https://www.fda.gov/drugs/development-resources/tigecycline-injection-products |
|
[5]
|
Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu YS, et al. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2022;60(3):106633. http://dx.doi.org/10.1016/j.ijantimicag.2022.106633CrossRef
|
|
[6]
|
Yang WW, Ding L, Han RR, Yin DD, Wu S, Yang Y, et al. Current status and trends of antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from 2018 to 2022. One Health Adv 2023;1(1):8. http://dx.doi.org/10.1186/s44280-023-00009-9CrossRef
|
|
[7]
|
Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-Lactam-β-Lactamase Inhibitor Combinations. Clin Microbiol Rev 2020;34(1):e00115 − 20. http://dx.doi.org/10.1128/CMR.00115-20CrossRef
|
|
[8]
|
Yu H, Xu XS, Li M, Yang QW, Yang Q, Zhang R, et al. Expert consensus statement on laboratory detection and clinical report of carbapenemase among Enterobacterales (second edition). Chin J Infect Chemother 2022;22(4):463 − 74. http://dx.doi.org/10.16718/j.1009-7708.2022.04.014 (In Chinese). CrossRef
|
|
[9]
|
Zeng M, Xia J, Zong ZY, Shi Y, Ni YX, Hu FP, et al. Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. J Microbiol Immunol Infect 2023;56(4):653 − 71. http://dx.doi.org/10.1016/j.jmii.2023.01.017CrossRef
|
|
[10]
|
Ding L, Chen BY, Li M, Ni YX, Shan B, Su DH, et al. Expert consensus on antimicrobial synergy testing, reporting of carbapenem-resistant Gram-negative bacteria. Chin J Infect Chemother 2023;1(23):80 − 90. http://dx.doi.org/10.16718/j.1009-7708.2023.01.013 (In Chinese). CrossRef
|
|
[11]
|
Ding L, Guo Y, Hu FP. Antimicrobial resistance surveillance: China's nearly 40-year effort. Int J Antimicrob Agents 2023;62(2):106869. http://dx.doi.org/10.1016/j.ijantimicag.2023.106869CrossRef
|